Signal Pharmaceuticals, Inc.

Rachel Ferri

Shripad S Bhagwat

John J Sapienza

Qi Chao

Yoshitaka Satoh

Chris Allen Buhr

Ronald J Albers

Steven T Sakata

Kiran Sahasrabudhe

Veronique Plantevin

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R, Rand A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Methods of using indazole derivatives as JNK inhibitors

This invention is generally directed to Indazole Derivatives having the following structure: or pharmaceutically acceptable salt thereof, wherein R, Rand A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure:wherein R, Rand A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Growing community of inventors

San Diego, CA, United States of America

Rachel Ferri